The Limbic

Don’t deny RA patients cancer immunotherapy

Patients with pre-existing rheumatoid arthritis receiving immune checkpoint inhibitors for malignancy experience severe immune related Adverse Events (irAEs) at a similar rate to other cancer patients without autoimmune diseases. A study of 84 RA patients with cancers such as melanoma and...

Patients with pre-existing rheumatoid arthritis receiving immune checkpoint inhibitors for malignancy experience severe immune related Adverse Events (irAEs) at a...

Guidelines for OA, gout, vasculitis previewed at #ACR19

Previews of draft guidelines for gout, vasculitis and osteoarthritis were up for discussion at the 2019 ACR/ARP Annual Meeting in Atlanta. The guideline documents, currently under peer review, are scheduled for publication in 2020. Here’s a summary of the some of...

Previews of draft guidelines for gout, vasculitis and osteoarthritis were up for discussion at the 2019 ACR/ARP Annual Meeting in...

Rheumatoid arthritis

Half of RA patients on biologics will switch: ARAD

Patterns of use for biologics in rheumatoid arthritis are complex, according to Australian research presented at the 2019 ACR/ARP Annual Meeting in Atlanta. According to an analysis of 3,470 participants in ARAD (Australian Rheumatology Association Database) from 2001 to 2018, first-line...

Patterns of use for biologics in rheumatoid arthritis are complex, according to Australian research presented at the 2019 ACR/ARP Annual...